The stock of Sana Biotechnology Inc. (NASDAQ:SANA) decreased by -$0.02 on Friday to finish at $5.46, down -0.36 percent. The last five days have seen an average of 911,120 shares of common stock traded. 17 times new highs were reached in the current year, with a gain of $1.51. The average number of shares traded over the last 20 days was 940,790, while the average volume over the last 50 days totaled 1,090,240.
SANA stock dropped -7.93% since last month. On 08/07/23, the company’s shares reached a one-month low of $5.04. The stock touched a high of $8.77 on 05/23/23, after rallying from a low of $2.99 in 52 weeks. The price of SANA stock has risen by 38.23% or $1.51 this year, reaching a new high 17 times. Still, the stock price is down -37.74% from the 52-week high.
Insider Transactions
SANA stock investors should be aware that Sana Biotechnology Inc. (SANA) stock had its last reported insider trading activity 68 days ago on Jun 07. On Jun 07, 10% Owner Flagship Ventures Fund V Gener sold 200,000 shares at $6.24 each. This transaction resulted in the insider making $1,247,940. On Jun 06, Flagship Ventures Fund V Gener sold 203,758 shares at a price of US$6.31. After the transaction, the insider now owns 1,403,037 shares. 10% Owner Flagship Ventures Fund V Gener had earlier sold 82,000 shares on May 26 for $6.23 a share. The transaction was completed for $510,573.
Financial Health
For the three months ended June 29, Sana Biotechnology Inc.’s quick ratio was 3.00, while its current ratio was 3.00, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $3.09 million and revenue of $272.56 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. SANA’s return on assets (ROA) during the last 12 months has been -45.60%. In the meantime, the return on equity (ROE) for the last 12 months was -78.30%.
Earnings Surprise
According to Sana Biotechnology Inc.’s quarterly financial report for the quarter that ended June 29, it had $152.13 million in cash and short-term investments. It was predicted that Sana Biotechnology Inc.’s quarterly earnings would be -$0.45, but it ended up being -$0.43, beating the consensus by -4.70%. At the end of Sana Biotechnology Inc.’s most recent quarter ended June 29, its liabilities totaled 352.12 million, while its total debt was $113.14 million. Equity owned by shareholders amounts to $196.94 million.
Technical Picture
Here’s a quick look at Sana Biotechnology Inc.’s (SANA) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 42.35%, suggesting the stock is Neutral, with a 53.65% historical volatility rate.
The stochastic %K and %D were 39.41% and 35.79% respectively, while the average true range (ATR) was 0.31. Based on the 14-day stochastic reading of 39.62%, the RSI (14) reading is 42.97%. On the 9-day MACD Oscillator, the stock is at 0.04, and the 14-day reading is at -0.09.
Analyst Ratings
In its analyst report released on May 02, 2023, H.C. Wainwright began covering Sana Biotechnology Inc. (NASDAQ: SANA). The stock was rated as a Neutral by the brokerage firm. Analysts have assigned Sana Biotechnology Inc. (SANA) an Hold rating. SANA is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is SANA’s price target for the next 12 months?
The current consensus forecast for the stock is between $6.00 and $11.00, with a median target price of $6.00. In analyzing these forecasts, the average price target given by analysts for Sana Biotechnology Inc. (SANA) is $7.67.
